Print PDF

Investors Night Out

05.02.2012

Wednesday, May 2, 2012
5:30 PM to 8:00 PM, Program starts at 6:30 PM
Cocktails and Heavy Hors d'oeuvres

Rancho Santa Fe Partners
6118 Paseo Delicias
Rancho Santa Fe, CA 92067

Investors Night Out is a private meeting of high net-worth investors and venture capitalists. The evening will provide an opportunity for investors to network with each other and the CEOs of companies that need early stage financing.  Each company will provide a 15 minute presentation on its business and specific financing needs.

This event is by invitation only.  Attendance is limited to qualified investors.

Please RSVP by April 26, 2012.

Presenting Companies:

MultiGEN Diagnostics, Inc.

Dr. T. V. Moorthy, CEO
858.523.1675
Moorthy@multigen-diagnostics.com.com
MultiGEN develops unique and proprietary molecular diagnostic test kits that provide compelling economic advantages: greatly enhanced test efficiency, accuracy, and cost reduction. MultiGEN technology is applicable to: (1) infectious diseases—pathogen identification and diagnosis); (2) genetic predisposition testing (“personal diagnostics”); and (3) genetic verification of treatment suitability, e.g., specific cancer mutations , viral therapy (“companion diagnosis”).  By using only one sample and performing a single test (“multiplex testing”), multiple pathogens and single-nucleotide polymorphism (SNPs) can be assayed.  With patent protection and initial market traction established, MultiGEN is well positioned to fulfill the unmet needs of the explosive molecular diagnostic and “personalized medicine” market. 

PlenSat, Inc.

Dr. Fred Voss, CEO
510.534.3255
fredv@plensat.com
PlenSat is developing a new approach to obesity control, the Digestible Balloon, which provides the benefits of bariatric surgery (stomach stapling, stomach banding, gastric bypass, and gastric balloon insertion) without medical intervention. This device promises to achieve many of the benefits of invasive bariatric surgery and endoscopically placed balloons without the risks and side effects of drugs and invasive procedures.  PlenSat’s novel approach utilizes a patented device constructed of organic materials currently being utilized in common foods.  The PlenSat digestible pill produces a sense of fullness, without the use of drugs.

DataPhysics Research, Inc.

Steve Douglas, CEO
925.984.1187
sdouglas@dpresearch.com
DataPhysics Research’s Intuitive Visualization technology cuts MRI, CT, and PET-CT post processing by almost half. DPR’s software product, CaseReader™, will replace today’s manually intensive radiology diagnostic report generation process. CaseReader™ provides a proprietary technology for radiologists and other healthcare professionals to take greater advantage of digital imaging technology. Referred to as a “game changing” solution by reviewing radiologists, CaseReader™ offers a “picture is worth a thousand words” benefit to its viewers. DPR’s technology prevents diagnostic errors, improves report turnaround times, and increases radiologic processing profitability. An NIH grant has been received, patent applications are pending, and initial channel distribution partnerships have been established.

Everloop, Inc.

Hilary DeCesare, CEO
816.531.3031
Hilary@everloopcrew.com
Everloop is the safe social network for kids, revolutionizing the way kids under 13 connect online. Unlike other social networking sites for kids, Everloop provides a unique, age-appropriate social media experience for children with customized micro-networks or "loops" that safely connect kid-relevant content, services, applications, and experiences.  Everloop provides the most comprehensive and fully Children’s Online Privacy Protection Act (COPPA) compliant social network with safety controls designed and built specifically for kids under 13. The Company recognizes the trust of parents and kids. With kids games online, safe email, photo exchange, and kids chat, Everloop is the kids’ social network where tweens can have fun on the internet,  safely being kids for as long as possible. 

Jump to Page

By scrolling this page, clicking a link or continuing to browse our website, you consent to our use of cookies as described in our Cookie and Advertising Policy. If you do not wish to accept cookies from our website, or would like to stop cookies being stored on your device in the future, you can find out more and adjust your preferences here.